Commenting on the momentous occasion, Malvinder Mohan Singh, CEO and managing director, said, "The introduction of atorvastatin in Denmark is a significant milestone in Ranbaxy's atorvastatin strategy and heralds the beginning of the company's determined efforts to bring affordable atorvastatin to patients in Europe and other parts of the world. Generic atorvastatin will bring significant and immediate cost benefits to the Danish healthcare system."

Ranbaxy will continue to actively pursue all options in the EU and other markets in order to bring affordable atorvastatin to patients around the world.

The company's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development.

The company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 9 countries.

Atorvastatin is a cholesterol-lowering drug, which is marketed by Pfizer as Lipitor.